HomeCompareXVIPF vs BTI

XVIPF vs BTI: Dividend Comparison 2026

XVIPF yields 8.77% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $2.0K in total portfolio value· pulled ahead in Year 9
10 years
XVIPF
XVIPF
● Live price
8.77%
Share price
$22.81
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$35.7K
Annual income
$1,524.79
Full XVIPF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — XVIPF vs BTI

📍 BTI pulled ahead of the other in Year 9

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodXVIPFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, XVIPF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
XVIPF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

XVIPF
Annual income on $10K today (after 15% tax)
$745.26/yr
After 10yr DRIP, annual income (after tax)
$1,296.07/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $1,072.57/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of XVIPF + BTI for your $10,000?

XVIPF: 50%BTI: 50%
100% BTI50/50100% XVIPF
Portfolio after 10yr
$36.7K
Annual income
$2,155.72/yr
Blended yield
5.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

XVIPF
Analyst Ratings
1
Buy
1
Sell
Consensus: Buy
Altman Z
16.5
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

XVIPF buys
0
BTI buys
0
No recent congressional trades found for XVIPF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricXVIPFBTI
Forward yield8.77%5.38%
Annual dividend / share$2.00$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%11.3%
Portfolio after 10y$35.7K$37.7K
Annual income after 10y$1,524.79$2,786.64
Total dividends collected$12.0K$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: XVIPF vs BTI ($10,000, DRIP)

YearXVIPF PortfolioXVIPF Income/yrBTI PortfolioBTI Income/yrGap
1$11,577$876.78$11,299$598.92+$278.00XVIPF
2$13,336$948.62$12,794$703.91+$542.00XVIPF
3$15,291$1,021.27$14,518$829.07+$773.00XVIPF
4$17,455$1,094.36$16,513$978.64+$942.00XVIPF
5$19,845$1,167.56$18,827$1,157.84+$1.0KXVIPF
6$22,474$1,240.55$21,518$1,373.12+$956.00XVIPF
7$25,361$1,313.03$24,657$1,632.46+$704.00XVIPF
8$28,521$1,384.72$28,329$1,945.74+$192.00XVIPF
9← crossover$31,972$1,455.38$32,637$2,325.33$665.00BTI
10$35,735$1,524.79$37,708$2,786.64$2.0KBTI

XVIPF vs BTI: Complete Analysis 2026

XVIPFStock

Xvivo Perfusion AB (publ), a medical technology company, develops solutions for organ, tissue, and cell preservation and perfusion in connection with transplantation in Sweden, the United States, North America and South America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers XVIVO System (XPS), an integrated off-the-shelf cardiac bypass system that includes various components needed to safely run normothermic ex vivo lung perfusion (EVLP); XPS Disposable Lung Kit that contains disposables and pre-packed products to suit requirement for sterility; and STEEN Solution, a buffered extracellular solution optimally designed to perfuse the isolated donor lung during EVLP. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XVIVO Silicone Tubing Set for rapid flushing of donor lungs during procurement; and XVIVO LS and XVIVO Disposable Lung Set, a device for EVLP. In addition, the company offers XVIVO Organ Chamber, a single-use sterile disposable container intended to be used as a temporary receptacle for isolated lungs in preparation for eventual transplantation into a recipient; and XVIVO Lung Cannula Set, a single-use, sterile disposable product. The company was incorporated in 1998 and is headquartered in Gothenburg, Sweden.

Full XVIPF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this XVIPF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

XVIPF vs SCHDXVIPF vs JEPIXVIPF vs OXVIPF vs KOXVIPF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.